{"id":3334,"date":"2025-03-24T14:15:34","date_gmt":"2025-03-24T11:15:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3334"},"modified":"2025-03-24T14:26:43","modified_gmt":"2025-03-24T11:26:43","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-45-201-a-phase-1-2-multiple-ascending-dose-clinical-study-of-entr-601-45-in-duchenne-muscular-dystrophy-patients-amenable-to-exon-45-sk\/","title":{"rendered":"Entrada Therapeutics erh\u00e4lt im Vereinigten K\u00f6nigreich die Genehmigung zur Einleitung von ELEVATE-45-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Entrada Therapeutics gab bekannt, dass es von der britischen Arzneimittelbeh\u00f6rde MHRA (Medicines and Healthcare Products Regulatory Agency) und der britischen Ethikkommission die Genehmigung zur Einleitung der Studie ELEVATE-45-201 erhalten hat. Bei ELEVATE-45-201 handelt es sich um eine klinische Studie der Phase 1\/2 mit aufsteigender Mehrfachdosis (MAD) zur Bewertung des Pr\u00fcfpr\u00e4parats ENTR-601-45 von Entrada zur potenziellen Behandlung der Duchenne-Muskeldystrophie (DMD) bei Patienten mit einer best\u00e4tigten Mutation im DMD-Gen, die f\u00fcr das Skipping von Exon 45 anf\u00e4llig ist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mehr erfahren: <a href=\"https:\/\/dmdwarrior.com\/de\/what-is-exon-skipping-and-how-does-it-work\/\" target=\"_blank\" data-type=\"post\" data-id=\"1445\" rel=\"noreferrer noopener\">Was ist Exon-Skipping?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Entrada Therapeutics, announced it has received authorization from the United Kingdom\u2019s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1\/2 multiple ascending dose (MAD) clinical study to evaluate Entrada\u2019s investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[320,321,234,317,318,319,48,322],"class_list":["post-3334","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-45-201","tag-entr-601-45","tag-entrada-therapeutics","tag-exon-45","tag-exon-45-skipping","tag-exon-45-skipping-therapy","tag-uk","tag-united-kingdom"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3334","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/3335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}